TWEAK/Fn14在骨关节炎患者中的表达及其临床意义被引量：4

Expressions and clinical significance of TWEAK/Fn14 in patients with osteoarthritis

下载PDF

导出

摘要目的:探讨TWEAK/Fn14在骨关节炎患者中的表达及其临床意义,为临床早期诊断骨关节炎探索新的方法。方法:收集35例骨关节炎患者为实验组,选择12例骨折患者作为对照组,采用ELISA方法检测两组人群血浆中TWEAK、RAN-TES、IL-18和IL-21水平,RT-PCR检测TWEAK mRNA在外周血单个核细胞和软骨细胞中的表达以及Fn14 mRNA在软骨细胞中的表达。结果:TWEAK、RANTES、IL-18、IL-21和ESR在实验组患者血浆中较对照组高表达(P<0.05)。在PBMC和软骨细胞中表达TWEAK mRNA,以及在软骨细胞表达Fn14mRNA,实验组均高于对照组(P<0.05)。结论:TWEAK在骨关节炎患者的血浆、PBMC和软骨细胞中高表达,Fn14在骨关节炎患者软骨细胞中高表达,表明TWEAK/Fn14可能参与了骨关节炎的病理发病过程,有望成为该病诊断的标志物。 Objective：To study the expressions and clinical significance of TWEAK/Fnl4 in patients with osteoarthritis and explore the novel diagnostic method for early osteoarthritis. Methods： 35 patients with osteoarthritis were collected as exprimental group and 12 fracture patients as control group. TWEAK, RANTES, IL-18 and IL-21expression in serum were detected by ELISA. TWEAK mRNA level was examined in peripheral blood mononuclear cells（PBMC） and chondrocytes by RT-PCR. Fnl4 rnRNA level was also examined in chondrocytes by RT-PCR. Results： TWEAK, RANTES, IL-18 and IL-21 expression were significantly higher in exprimental group than the normal group （P 〈 0.05）. TWEAK mRNA expression in PBMC and chondrocytes, and Fnl4 mRNA expression in chondro- cytes were higher in exprimental group than the control group （P 〈 0.05 ）. Conclusion： The increased expression of TWEAK and Fnl4 in patients with osteoarthritis suggests that TWEAK/Fn14 plays an important role in the pathogenesis of osteoarthritis. Furthermore, TWEAK and Fnl4 may be as a promising biomarker for diagnosis of the osteoarthritis.

作者陈琼赵明才蒋萍廖涛魏芃吴青许媛蒋红

机构地区川北医学院附属医院检验科川北医学院风湿免疫研究所川北医学院附属医院骨科

出处《川北医学院学报》 CAS 2013年第4期301-304,共4页 Journal of North Sichuan Medical College

基金国家自然科学基金(30972749) 四川省科技厅应用基础项目(2008JY0013)

关键词肿瘤坏死因子样弱凋亡诱导剂骨关节炎生物标志物 TWEAK Osteoarthritis Biomarker

分类号 R684.3 [医药卫生—骨科学]

引文网络
相关文献

参考文献1

1陈琼,赵明才,蒋萍,廖涛,蔚芃,吴青,蒋红.肿瘤坏死因子样微弱凋亡诱导因子对骨关节炎软骨细胞作用实验研究[J].检验医学与临床,2013,10(16):2065-2066. 被引量：6

二级参考文献11

1Rubin RJ,Dietrich KA, Hawk AD. Clinical and economic impact of implementing a comprehensive diabetes management program in managed care[J]. J Clin Endocrinol Metab, 1998,83(8) .. 2635-2642.
2Winkles JA. The TWEAK-Fnl4 cytokine-receptor axis: discovery, biology and therapeutic targeting E J]. Nat Rev Drug Discov, 2008,7 ( 5 ) .. 411-425.
3Haas S, Straub RH. Disruption of rhythms of molecular clocks in primary synovial fibroblasts of patients with os- teoarthritis and rheumatoid arthritis, role of IL-113/TNF. [J]. Arthritis Res Ther,2012,14(3) ..122 125.
4Perper SJ, Browning B, Burkly LC, et al. TWEAK is a no- vel arthritogenic mediator[J]. J Immunol, 2006,177 (4) : 2610-2620.
5Lim H,Park H, Kim HP. Effects of flavonoids on matrix metalloproteinase-13 expression of interleukin-ll3-treated articular chondrocytes and their cellular mechanisms:inhi- bition of e-Fos/AP-1 and JAK/STAT signaling pathways [J]. J Pharmacol Sci,2011,116(2) :221-231.
6Yamana J, Morand EF, Manabu T, et al. Inhibition of TNFinduced IL-6 by the TWEAK-Fn14 interaction in rheumatoid arthritis fibroblast like synoviocytes[J]. Cell Immunol,2012, 272(2) ..293 298.
7Ikner A, Ashkenazi A. TWEAK induces apoptosis through a death-signaling complex comprising recepto]interacting pro- tein 1 (RIP1), Fas-associated death domain (FADD), and caspase-8[J]. J Biol Chem,2011,286(24) :21546 21554.
8Dharmapatni AA, Smith MD, Crotti TN, et al. TWEAK and Fn14 expression in the pathogenesis of joint inflam marion and bone erosion in rheumatoid arthritis[J]. Ar- thritis Res Ther,2011,13(2) :RS1.
9Saitoh T, Nakayama M, Nakano H, et al. TWEAK in duces NF-kappaB2 pl00 processing and long lasting NF kappaB activation[J]. Biol Chem, 2003,278 (38) : 36005 36012.
10Chen HN,Wang DJ,Ren MY,et al. TWEAK/Fn14 pro motes the proliferation and collagen synthesis of rat cardi ac fibroblasts via the NF-]B pathway[J]. Mol Biol Rep 2012,39 (8) : 8231-8241.